To avoid a messy, billion-dollar U.S. patent fight over CRISPR-Cas9, Chinese biotech startups are engineering proprietary DNA scalpels from scratch
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Analysis: China Races to Build Its Own Gene-Editing Toolkit — With an AI Assist
To avoid a messy, billion-dollar U.S. patent fight over CRISPR-Cas9, Chinese biotech startups are engineering proprietary DNA…
Technique to precisely edit large DNA segments could transform disease research, crop breeding, experts say.
The policy push aims to cultivate ‘new quality productive forces’ in agriculture, boosting domestic biotech startups and paving…
Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans…
The death of a six-year-old patient in an investigator-initiated study highlights systemic vulnerabilities in ethics reviews,…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink
